Navigate - Improving Survival and Quality of Life in Vulnerable Lung Cancer Patients

Summary

Half of patients with lung cancer face a limited life span of one-year survival, which is characterized by severe physical and psychological symptoms. Differences in stage, comorbidity but also treatment may explain a large proportion of the social inequality in lung cancer survival. Some vulnerable patients may not receive first line treatment as planned either due to poor performance status or if they are not able to adhere to treatment appointments. Knowing how to navigate the health system may be a barrier preventing vulnerable patients in receiving optimal treatment. The primary aim of this randomised, controlled trial is to test whether a nurse-led individually tailored program including systematic screening of symptoms using PROs and a physical training program will significantly improve a composite outcome of survival and quality of life as the primary outcome among vulnerable lung cancer patients compared with standard care. Secondary outcomes include adherence to cancer treatment, symptom burden and overall survival.

Conditions

• Lung Cancer

Interventions

BEHAVIORAL

NAVIGATE

Patients' symptoms are systematically monitored by use of bi-weekly patient reported outcomes and nurse navigators will initiate appropriate actions in terms of medical treatment or guidance of self-management strategies. Nurse navigators will motivate and support patients in health behavior changes and in selfmanaging their treatment and symptoms, and, if relevant, refer to existing rehabilitation services at the hospital or at the local rehabilitation center. Physiotherapists will supervise a training program aimed at improving patients' physical function and thus potentially surgery and overall treatment adherence and outcomes.

Sponsors & Collaborators

• Danish Cancer Society

  collaborator OTHER

• Odense University Hospital

  collaborator OTHER

• Vejle Hospital

  collaborator OTHER

• Hospital of Southern Jutland

  collaborator OTHER

• Zealand University Hospital

  lead OTHER

Principal Investigators

• Susanne O Dalton, Professor · Zealand University Hospital

• Pernille E Bidstrup, PhD · Danish Cancer Society

• Erik Jakobsen, PhD · The Danish Lung Cancer Research Center

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-03-01

Primary Completion

2026-12-31

Completion

2026-12-31

Countries

• Denmark

Study Locations